Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will wrestle with how to include an unapproved diagnostic test in expanded labeling for Pfizer's HIV drug.